1068. MicroRNA-regulated immunosuppression in severely injured polytrauma patients
© Owen et al; licensee Springer. 2014
Published: 26 September 2014
We have demonstrated that traumatic injury is associated with an early immunosuppressive response, the extent of which is associated with an increased risk of developing nosocomial infections. In particular, the expression of the immunosuppressive cytokine IL-10 was up-regulated 2 hours following injury . However, the mechanisms involved are unclear. MicroRNAs (miRs) are short non-coding RNA molecules whose main function is to down-regulate gene expression. Although preliminary laboratory data suggest alterations in miR expression may play a role in triggering this immunosuppressive phenotype there is currently a lack of data in trauma patients [2, 3].
To explore alterations in candidate miR expression that may regulate the immunosuppressive phenotype following severe trauma and evaluate their potential role in enhancing the risk of nosocomial infections.
Following ethics approval and consent, 30 ICU patients admitted following severe traumatic injury and 16 healthy age and sex matched controls were recruited. miRs were isolated utilising PAX Gene and miRNA-Easy extraction kits (Qiagen). miRs were selected for analysis based on miRBase target prediction scores for the IL10 promoter. Candidate miRs were quantified by qPCR at 2 hours and 24 hours following injury and then normalised to the small nucleolar RNAs RNU44 and RNU48. Infections were assessed using predefined criteria.
The expression of miRs with high predicted complementarity to the IL-10 promoter decrease following a severe traumatic injury. It is plausible that this reduction in inhibitory miRs is an important mechanism for the increase in IL-10 gene expression that is seen in these patients and thereby contributes to the consequent immunosuppressive phenotype and increased risk of nosocomial infections.
This work was funded by a Barts and the London Charity Grant.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.